Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akso Health GroupAHG +2.72%36 Debt-to-EBITDA is -0.13 as of Mar. 2026. GuruFocus rates AHG with a GF Score™ of 36/100 and a GF Value™ of $0.40 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 90 Medical Distribution companies, Akso Health Group ranks worse than 1111110% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Akso Health Group's Debt-to-EBITDA or its related term are showing as below:
AHG'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.68 Med: -0.47 Max: -0.05
Current: -0.23
During the past 12 years, the highest Debt-to-EBITDA Ratio of Akso Health Group was -0.05. The lowest was -4.68. And the median was -0.47.
AHG's Debt-to-EBITDA is ranked worse than 100% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs AHG: -0.23
Akso Health Group (NAS:AHG) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Akso Health Group Debt-to-EBITDA Related Terms
Akso Health Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Akso Health Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Akso Health Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akso Health Group Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Akso Health Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Akso Health Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Akso Health Group (AHG) has a Debt-to-EBITDA of -0.13 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Akso Health Group. According to the industry distribution chart, Akso Health Group ranks #999999 out of 90 companies in the Medical Distribution industry.
Is Akso Health Group's Debt-to-EBITDA too high?
Akso Health Group's current Debt-to-EBITDA is -0.13. Based on the distribution chart, Akso Health Group ranks #999999 out of 90 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Akso Health Group has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Akso Health Group's Debt-to-EBITDA compare to ACH and FOCL?
According to the Medical Distribution industry distribution chart, Akso Health Group ranks #999999 out of 90 companies for Debt-to-EBITDA. This places Akso Health Group in the lower half of its industry. The industry median Debt-to-EBITDA is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Akso Health Group. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akso Health Group's current Debt-to-EBITDA is -0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akso Health Group stock overvalued right now?
Based on GuruFocus' analysis, Akso Health Group (AHG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.40, compared to a current price of $1.53 — trading 281.3% above its estimated fair value. The current Debt-to-EBITDA is -0.13. Akso Health Group's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Akso Health Group (AHG), the current Debt-to-EBITDA is -0.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akso Health Group (AHG) Overvalued in 2026?
Based on GuruFocus' analysis, Akso Health Group stock appears to be overvalued.
The current stock price of $1.53 is trading 281.3% above its estimated GF Value™ of $0.40.
GuruFocus considers Akso Health Group to be Significantly Overvalued.
Key valuation signals for AHG:
Debt-to-EBITDA: -0.13
GF Value™: $0.40 vs. price of $1.53 (281.3% above fair value)
No single metric tells the full story. See the AHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
36GF Score
Get the complete analysis for AHG
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AHG has been successfully added to your 
